JP2013501751A - 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター - Google Patents

経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター Download PDF

Info

Publication number
JP2013501751A
JP2013501751A JP2012524227A JP2012524227A JP2013501751A JP 2013501751 A JP2013501751 A JP 2013501751A JP 2012524227 A JP2012524227 A JP 2012524227A JP 2012524227 A JP2012524227 A JP 2012524227A JP 2013501751 A JP2013501751 A JP 2013501751A
Authority
JP
Japan
Prior art keywords
compound
formulation
acid
ethyl
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012524227A
Other languages
English (en)
Japanese (ja)
Inventor
タークル,ジーワン
ヤン,ドン
フォン,リリー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013501751(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013501751A publication Critical patent/JP2013501751A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012524227A 2009-08-12 2010-08-11 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター Withdrawn JP2013501751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
US61/274,051 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060543A Division JP2016179976A (ja) 2009-08-12 2016-03-24 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター

Publications (1)

Publication Number Publication Date
JP2013501751A true JP2013501751A (ja) 2013-01-17

Family

ID=42937834

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012524227A Withdrawn JP2013501751A (ja) 2009-08-12 2010-08-11 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
JP2016060543A Ceased JP2016179976A (ja) 2009-08-12 2016-03-24 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
JP2018116705A Pending JP2018172403A (ja) 2009-08-12 2018-06-20 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016060543A Ceased JP2016179976A (ja) 2009-08-12 2016-03-24 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
JP2018116705A Pending JP2018172403A (ja) 2009-08-12 2018-06-20 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター

Country Status (24)

Country Link
US (4) US8623385B2 (enExample)
EP (1) EP2464644A1 (enExample)
JP (3) JP2013501751A (enExample)
KR (2) KR20120048008A (enExample)
CN (2) CN105646471A (enExample)
AR (1) AR077869A1 (enExample)
AU (4) AU2010283748A1 (enExample)
BR (1) BR112012003118A2 (enExample)
CA (1) CA2769616A1 (enExample)
CL (1) CL2012000349A1 (enExample)
CO (1) CO6612189A2 (enExample)
IL (1) IL217760A0 (enExample)
IN (1) IN2012DN00858A (enExample)
MA (1) MA33511B1 (enExample)
MX (2) MX2012001844A (enExample)
MY (1) MY160475A (enExample)
PE (2) PE20121132A1 (enExample)
PH (1) PH12014501890B1 (enExample)
RU (1) RU2671196C1 (enExample)
SG (1) SG177713A1 (enExample)
TN (1) TN2012000026A1 (enExample)
TW (1) TWI607006B (enExample)
WO (1) WO2011018474A1 (enExample)
ZA (1) ZA201200390B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311867A (zh) 2016-04-20 2019-02-05 葛兰素史克知识产权开发有限公司 包含ripk2抑制剂的共轭物
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502861A (ja) * 2001-08-10 2005-01-27 サイミックス テクノロジーズ, インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
JP2007532504A (ja) * 2004-04-07 2007-11-15 ノバルティス アクチエンゲゼルシャフト Iapの阻害剤
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502861A (ja) * 2001-08-10 2005-01-27 サイミックス テクノロジーズ, インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
JP2007532504A (ja) * 2004-04-07 2007-11-15 ノバルティス アクチエンゲゼルシャフト Iapの阻害剤
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第568号, JPN6010021254, 2001, ISSN: 0003199189 *
BASTIN,R.J. ET AL: "Salt selection and optimization procedures for pharmaceutical new chemical entities", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, no. 5, JPN6009059058, 2000, pages 427 - 435, ISSN: 0003199187 *
CAIRA,M. R.: ""Crystalline Polymorphism of Organic Compounds"", TOPICS IN CURRENT CHEMISTRY, vol. 198, JPN5012016574, 1 January 1998 (1998-01-01), pages 163 - 208, ISSN: 0002934998 *
STAHLY,P.: ""医薬品の塩選択,結晶多形のスクリーニングの重要性について"", 薬剤学, vol. 66, no. 6, JPN6013022474, 2006, pages 435 - 439, ISSN: 0003199185 *
大島寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0003199183 *
小嶌隆史 他: ""医薬品開発における結晶形の効率的選択 −塩・結晶多形スクリーニングへのラマン分光法の応用−"", PHARM TECH JAPAN, vol. 23, no. 12, JPN6013022471, 1 November 2007 (2007-11-01), pages 173 - 2461, ISSN: 0003199184 *
小嶌隆史 他: ""塩及び結晶形選択による結晶性医薬品候補化合物の物理的安定性の改善"", 薬剤学, vol. 67, JPN7013001759, 10 May 2007 (2007-05-10), pages 426, ISSN: 0003199186 *
松本光雄 他 編, 『薬剤学マニュアル』, vol. 第1版, JPN6009059501, 20 March 1989 (1989-03-20), pages 28, ISSN: 0003199188 *
高田則幸: ""創薬段階における原薬 Form スクリーニングと選択"", PHARM STAGE, vol. 6, no. 10, JPN6010003275, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0003199182 *

Also Published As

Publication number Publication date
RU2671196C1 (ru) 2018-10-30
AR077869A1 (es) 2011-09-28
CN105646471A (zh) 2016-06-08
US20180370960A1 (en) 2018-12-27
JP2018172403A (ja) 2018-11-08
EP2464644A1 (en) 2012-06-20
US20170081319A1 (en) 2017-03-23
CA2769616A1 (en) 2011-02-17
MX2012001844A (es) 2012-02-29
PE20121132A1 (es) 2012-09-04
AU2010283748A1 (en) 2012-02-09
CN102471331B (zh) 2016-01-13
US9540363B2 (en) 2017-01-10
TW201118091A (en) 2011-06-01
MY160475A (en) 2017-03-15
AU2016203145A1 (en) 2016-06-02
AU2017254950A1 (en) 2017-11-23
MX351274B (es) 2017-10-06
US8623385B2 (en) 2014-01-07
KR20120048008A (ko) 2012-05-14
US20140093570A1 (en) 2014-04-03
KR20180020315A (ko) 2018-02-27
PH12014501890A1 (en) 2015-09-14
IL217760A0 (en) 2012-03-29
AU2017254950B2 (en) 2018-09-20
US10093665B2 (en) 2018-10-09
TN2012000026A1 (en) 2013-09-19
PE20170777A1 (es) 2017-07-04
TWI607006B (zh) 2017-12-01
IN2012DN00858A (enExample) 2015-07-10
US20120128742A1 (en) 2012-05-24
CL2012000349A1 (es) 2012-09-07
JP2016179976A (ja) 2016-10-13
WO2011018474A1 (en) 2011-02-17
ZA201200390B (en) 2012-10-31
MA33511B1 (fr) 2012-08-01
SG177713A1 (en) 2012-02-28
CN102471331A (zh) 2012-05-23
CO6612189A2 (es) 2013-02-01
RU2012108931A (ru) 2013-09-27
PH12014501890B1 (en) 2015-09-14
BR112012003118A2 (pt) 2016-02-23
WO2011018474A8 (en) 2011-09-22
AU2014213533A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
TWI826446B (zh) Tlr7/tlr8抑制劑之晶型
TWI846166B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
JP5584705B2 (ja) R)−3−(4−(2−(2−メチルテトラゾール−5−イル)ピリジン−5−イル)−3−フルオロフェニル)−5−ヒドロキシメチルオキサゾリジン−2−オンリン酸二水素の結晶形
CN103842360B (zh) 用于药物制剂的具有特定粒度分布范围和比表面积范围的n-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
WO2007097386A1 (ja) 安定化医薬組成物
JP2018172403A (ja) 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
TW202110823A (zh) N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
TW202444377A (zh) 包括ent1抑制劑之鹽、結晶形式及水合物與溶劑合物的硫酸氫複合物
JP2018518515A (ja) フェニルアミノピリミジン化合物またはその塩の多形物
RU2574405C2 (ru) Твердые пероральные составы и кристаллические формы ингибитора белка апоптоза
RU2836337C2 (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
CN110678464A (zh) 马赛替尼的晶型
TW202434612A (zh) 一種二肽類化合物的鹽、其製備方法和用途
TW202521117A (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1196017A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151124

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160512